ObsEva will cut staff by 70% after FDA setback for uterine fibroids candidate linzagolix

ObsEva will cut staff by 70% after FDA setback for uterine fibroids candidate linzagolix

Submitted by admin on September 13, 2022 - 7:53pm
Source: 
Fierce Pharma
News Tags: 
ObsEva
uterine fibroids
linzagolix
layoffs
Headline: 
ObsEva will cut staff by 70% after FDA setback for uterine fibroids candidate linzagolix
snippet: 

After the FDA delivered bad news to ObsEva in July—saying its highly touted uterine fibroids candidate linzagolix wasn’t fit for an on-time approval—the Swiss company said it would undergo a drastic restructuring.

Do Not Allow Advertisers to Use My Personal information